Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Ergomed plc
  6. News
  7. Summary
    ERGO   GB00BN7ZCY67

ERGOMED PLC

(ERGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ergomed : Zizi Uzezi Imatorbhebhe appointed as the new Senior Vice President, Global Strategy & Development, Rare Disease

11/24/2021 | 08:10am EST

Ergomed is pleased to welcome Zizi Uzezi Imatorbhebhe, MBA, MS PMP® as the new Senior Vice President, Global Strategy & Development, Rare Disease.

Zizi is a seasoned executive with over 32+ years of drug development and commercial experience in the Bio-pharmaceutical, Clinical Research (CRO) and Healthcare industry. She has been instrumental in working collaboratively with many global sponsors especially in the Rare Disease space to identify drug development challenges for their programs and providing solutions to address them. She has also successfully commercialized over 25 pharmaceutical and medical device products globally. In addition, she works to leverage innovations to develop patient-oriented solutions and expand clinical trial access.

Her Educational background includes MS in Biotechnology from the University College London, UK MBA from Chapman University, California US, BS in Biochemistry from the University of Ibadan, Nigeria. In addition, she has an Executive Management Certificate in Disruptive Strategies and Innovation from Harvard Business School, Boston, US and is Lean Six Sigma trained.

Zizi has successfully developed and optimized Rare Disease Initiatives and Centers of Excellence at leading organizations and is a published subject matter expert in this space. She is passionate about bringing treatments to Rare Disease patients due to the high unmet need with 95% of Rare Diseases without treatment. Approximately 50 percentof rare diseases affect children, 30 percentof whom will not live to see their fifth birthday.

Zizi shared "Rare Disease development is one of the fastest-growing areas of drug development accounting for over 30% of compounds in development. I am excited to be expanding our global efforts to growing our Rare Disease Business, strengthening collaborations with biopharmaceutical sponsor companies, patient advocacy groups, innovative technology and service providers to accelerate rare disease drug development and bring much-needed treatments to patients around the world".

Please, join us in welcoming Zizi to the Ergomed Team!

If you require further information, please do not hesitate to contact us.

Disclaimer

Ergomed plc published this content on 24 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2021 13:09:06 UTC.


ę Publicnow 2021
All news about ERGOMED PLC
01/25London Shares Gain as Miners, Oil Stocks and Royal Mail Rise
DJ
01/25Ergomed Flags 37% Revenue Rise in 2021 on Strong Trading Performance
MT
01/25Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021
CI
01/11Diaceutics Hires Ergomed Official as CFO
MT
01/10ERGOMED : Dr. Marie-Edith Bonneterre appointed as Ergomed Vice President, Head of Global M..
PU
2021Ergomed plc Appoints Roger Holden as Senior Director, Quality Assurance
CI
2021ERGOMED : Roger Holden appointed as Ergomed Senior Director, Quality Assurance
PU
2021ERGOMED : Zizi Uzezi Imatorbhebhe appointed as the new Senior Vice President, Global Strat..
PU
2021ERGOMED : Jefferies London Healthcare Conference – Presentation by Ergomed Executive..
PU
2021New Ergomed e-Book 'Data Protection in Europe-based Clinical Trials' now available
AQ
More news
Financials
Sales 2021 120 M 162 M 162 M
Net income 2021 12,8 M 17,3 M 17,3 M
Net cash 2021 29,3 M 39,5 M 39,5 M
P/E ratio 2021 43,7x
Yield 2021 -
Capitalization 565 M 762 M 763 M
EV / Sales 2021 4,48x
EV / Sales 2022 3,86x
Nbr of Employees 1 150
Free-Float 79,6%
Chart ERGOMED PLC
Duration : Period :
Ergomed plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERGOMED PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1 150,00 GBX
Average target price 1 490,00 GBX
Spread / Average Target 29,6%
EPS Revisions
Managers and Directors
Richard Timothy Barfield Chief Financial Officer & Executive Director
Miroslav Reljanovic Executive Chairman
Gordana Tonkovic Head-Clinical Development
Sladana Sturlic Head-Clinical Operations
Marie-Edith Bonneterre Vice President & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ERGOMED PLC-23.33%762
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796